Score Overview
Explore the 2021 public Archive ranking →
Where Alnylam Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. ALNY does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 255.36 | — |
1 Year2025-09-26 | $ 446.40 | -42.80% |
5 Years2021-09-28 | $ 177.08 | 44.21% |
10 Years2016-09-28 | $ 76.67 | 233.06% |
20 Years2006-09-28 | $ 14.48 | 17x |
All Time2004-05-28 | $ 6.01 | 42x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | All Time2004-05-28 |
|---|---|---|---|---|---|---|
| Price | $ 255.36 | $ 446.40 | $ 177.08 | $ 76.67 | $ 14.48 | $ 6.01 |
| Return | — | -42.80% | 44.21% | 233.06% | 17x | 42x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 4.80B | $ 807M | $ 3.30B |
| 2025 | $ 3.71B | $ 313M | $ 2.90B |
| 2024 | $ 2.24B | -$ 278M | $ 2.69B |
| 2023 | $ 1.82B | -$ 440M | $ 2.43B |
| 2022 | $ 1.03B | -$ 1.13B | $ 2.19B |
| 2021 | $ 844M | -$ 852M | $ 2.43B |
| 2020 | $ 492M | -$ 858M | $ 1.87B |
| 2019 | $ 219M | -$ 886M | $ 1.53B |
| 2018 | $ 74M | -$ 761M | $ 1.08B |
| 2017 | $ 89M | -$ 490M | $ 1.70B |
| 2016 | $ 47M | -$ 410M | $ 942M |
| 2015 | $ 41M | -$ 290M | $ 1.08B |
| 2014 | $ 50M | -$ 360M | $ 696M |
| 2013 | $ 47M | -$ 89M | $ 245M |
| 2012 | $ 66M | -$ 106M | $ 122M |
| 2011 | $ 82M | -$ 57M | $ 146M |
| 2010 | $ 100M | -$ 43M | $ 233M |
| 2009 | $ 100M | -$ 47M | $ 281M |
| 2008 | $ 96M | -$ 26M | $ 430M |
| 2007 | $ 50M | -$ 85M | $ 389M |
| 2006 | $ 26M | -$ 34M | $ 217M |
| 2005 | $ 5M | -$ 42M | $ 80M |
| IPO2004 | $ 4M | -$ 32M | $ 46M |
Alnylam Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 492M to $ 3.71B and net income went from -$ 858M to $ 313M. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 41M to $ 3.71B and net income went from -$ 290M to $ 313M. Revenue increased in 9 of those 10 years; net income in 6.
Alnylam Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.
Membership
Explore ALNY with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
